Precision Point Devices v. Huawei — Dismissed With Prejudice After 211 Days
Precision Point Devices LLC filed suit against Huawei Technologies and Huawei Device USA in the Northern District of Texas, asserting two patents covering health check systems and information service platforms. The case resolved and was dismissed with prejudice in approximately seven months, with each party bearing its own costs.
A seven-month patent dispute over connected health and information service IP
On 9 February 2023, Precision Point Devices LLC filed an infringement action in the Northern District of Texas (Case No. 3:23-cv-00306) against Huawei Technologies Co. Ltd. and Huawei Device USA Inc., asserting US8583452B2, which covers a health check system, apparatus, and method, and US8566060B2, directed to an information service providing system and device.
The case closed on 8 September 2023 — 211 days after filing. The recorded Basis of Termination is Dismissed with Prejudice. The docket order states that the parties reached a settlement and that, pursuant to Rule 41(a)(1)(A)(i), Precision Point submitted a voluntary dismissal with prejudice of all claims against Huawei, with each party bearing its own costs, expenses, and attorney's fees.
Resolution in roughly seven months, before any publicly recorded claim construction or trial activity, is consistent with an early settlement. The specific terms of any underlying settlement agreement are not disclosed in the available record. What is clear is that the dismissal is with prejudice, meaning Precision Point cannot reassert the same claims against Huawei arising from the same conduct in a future action.
See Complete Case & Patent Analysis →Filing to Dismissed with Prejudice in 211 days
211 days from filing to dismissal — resolved well within the typical district court trial window
US8583452B2 & US8566060B2 — Health Check Systems and Information Service Platforms
Any organisation developing connected health monitoring systems, IoT diagnostic platforms, or networked information service architectures should treat these patents as live enforcement risks. The with-prejudice dismissal against Huawei provides no third-party protection. If your product performs health-status reporting across devices or delivers information services over a managed network, an FTO review of both US8583452B2 and US8566060B2 is warranted.
Official order — verbatim text
The dismissal order records a Rule 41(a)(1)(A)(i) voluntary dismissal with prejudice submitted by Precision Point following a reported settlement. The with-prejudice designation is the legally operative element: it extinguishes the asserted claims permanently as against Huawei. The cost-bearing provision — each side pays its own fees — signals a negotiated exit with no fee-shifting. The specific terms of any underlying agreement are not disclosed in the available record.
Dismissed with prejudice: what the resolution means for both parties
Dismissal with prejudice bars future re-filing of the same claims
A dismissal with prejudice is a final, on-the-merits termination. Precision Point cannot re-file the same patent infringement claims against Huawei arising from the same underlying conduct. The dismissal was entered via Rule 41(a)(1)(A)(i), a plaintiff's voluntary notice of dismissal, submitted following the parties' reported settlement. The order specifies each party bears its own costs.
Plaintiff-filed voluntary dismissalPrecision Point's claims are permanently extinguished against Huawei
With both patents dismissed with prejudice, Precision Point Devices cannot pursue Huawei under US8583452B2 or US8566060B2 for the conduct alleged in this action. The underlying patents themselves remain in force and could potentially be asserted against other parties, but the specific terms of any settlement between these parties are not disclosed in the available record.
No further Huawei exposure on this recordHuawei secures finality on these two patents in this jurisdiction
The dismissal with prejudice provides Huawei Technologies and Huawei Device USA with a final resolution: Precision Point's infringement claims under the asserted health check and information service patents cannot be revived in this venue for the same conduct. The cost-neutral order means no fee-shifting occurred, which is consistent with a negotiated exit rather than a contested merits ruling.
Claims extinguished, costs neutralUS8583452 and US8566060 remain live assets post-dismissal
Precision Point's underlying patents covering health check systems and information service platforms are not invalidated by this dismissal — they remain enforceable against third parties. Companies in the connected health, IoT monitoring, or information service sectors whose products fall within these claims face potential assertion risk. A freedom-to-operate analysis against both patents remains relevant for product teams in these technology areas.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Precision Point Devices LLC | Company | /Search in Eureka ↗ |
| Defendant | Huawei Technologies, Co., Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Huawei Device USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Kirk Anderson | Attorney | Counsel for Precision Point Devices LLCSearch in Eureka ↗ |
| Plaintiff law firm | Budo Law PC | Law Firm | Representing Precision Point Devices LLCSearch in Eureka ↗ |
| Presiding judge | Judge Barbara M. G. Lynn | Judge | Texas Northern District CourtSearch in Eureka ↗ |
R&D signals in the connected health and information service patent space
Forward-looking patent intelligence derived from the Precision Point Devices v. Huawei dispute — mapping portfolio activity, technology filing trends, and white space around the asserted patents.
Precision Point's health and information service patent holdings
Precision Point Devices asserted two patents covering distinct but complementary system layers in this action. Understanding the full scope of their portfolio — including any continuations, divisionals, or related family members of US8583452 and US8566060 — is critical for predicting future assertion targets and licensing posture in connected health and device management technologies.
Portfolio watch: Precision PointFiling trends in health check and networked information service architectures
Patent filing activity around health check systems, device diagnostic monitoring, and information service delivery platforms has grown alongside IoT and connected device adoption. Mapping recent filing trends in these sub-domains can reveal which players are building defensive positions and where assertion risks are concentrating — particularly relevant given the claim scope of US8583452B2 and US8566060B2.
IoT health monitoring filing trendsHuawei's defensive patent portfolio in device management and health monitoring
Huawei Technologies holds an extensive patent portfolio spanning telecommunications infrastructure, consumer devices, and network management. Mapping Huawei's own filings in health check, device diagnostics, and information service platforms can reveal whether the company has built defensive IP in these domains that could be leveraged in future disputes or cross-licensing negotiations.
Huawei defensive IP in device healthAdjacent innovation space around health check apparatus and service delivery
The claim architecture of US8583452B2 and US8566060B2 leaves adjacent technical areas — such as AI-driven predictive health monitoring, edge-computed diagnostics, and personalised information service routing — potentially underprotected by existing filings. R&D teams designing next-generation connected health or service delivery platforms may find meaningful white space in these adjacent sub-domains.
White space: AI health diagnosticsSimilar patent infringement cases in health check and information service systems
Explore comparable infringement actions involving health check, device monitoring, and information service platform patents filed in the Northern District of Texas and related federal venues.
What this case signals for the connected health and information service IP landscape
A swift, cost-neutral resolution against one of the world's largest tech defendants highlights the assertion dynamics around health check and information service system patents.
Early resolution signals assertion-focused strategy against device manufacturers
Settling in 211 days — before claim construction — is consistent with a monetisation posture rather than a bid for injunctive relief. Companies in the connected health and information service device space should monitor Precision Point's portfolio for further assertion activity against other defendants.
Dismissed with prejudice limits Huawei's exposure but not other defendants'
The with-prejudice dismissal protects Huawei specifically on this record. Other companies with products potentially within the scope of US8583452B2 or US8566060B2 receive no preclusive benefit from this outcome. Independent FTO analysis remains necessary for any third party operating in health check or information service system product categories.
Precision v Huawei — key questions answered
The case was dismissed with prejudice on 8 September 2023, approximately 211 days after filing. The dismissal was entered pursuant to Rule 41(a)(1)(A)(i) following the parties' reported settlement. Each party bears its own costs, expenses, and attorney's fees. The specific terms of any underlying settlement are not disclosed in the available record.
Precision Point Devices asserted two patents: US8583452B2 (App. No. 12/640967), covering a health check system, apparatus, and method, and US8566060B2 (App. No. 12/665107), directed to an information service providing system and device. Both patents remain in force following the dismissal.
No. A dismissal with prejudice only bars Precision Point from re-asserting the same claims against Huawei for the same conduct alleged in this action. Third parties — including other device manufacturers and information service platform providers — receive no preclusive benefit from this outcome. Independent freedom-to-operate analysis against US8583452B2 and US8566060B2 remains necessary for other companies.
US8583452B2 covers a health check system, apparatus, and method — addressing how devices or network nodes monitor and report health or diagnostic status. US8566060B2 covers an information service providing system and device. Companies developing connected health monitoring platforms, IoT diagnostic tools, or networked information service delivery systems may face assertion risk if their products fall within these claims.
The Northern District of Texas is a venue frequently chosen by patent assertion entities due to its established patent dockets and experienced judges. The record does not disclose the specific jurisdictional basis beyond the filing, but the N.D. Texas has become a significant forum for patent infringement actions against technology companies with operations or sales in the district.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.